157 results on '"Bloomquist, Erik"'
Search Results
2. Supplementary Table S2 from FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma
3. Supplementary Figure S1 from FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma
4. Data from FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma
5. FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma
6. Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis
7. FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
8. US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.
9. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
10. Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer
11. An Empirical Investigation of Bayesian Clinical Trial Design in Metastatic Breast Cancer
12. FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA -Mutated Metastatic Castration-Resistant Prostate Cancer.
13. FDA pooled analysis of overall survival according to depth of response as a continuous variable in frontline advanced immuno-oncology renal cell carcinoma trials.
14. FDA Approval Summary: Ribociclib Indicated for Male Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
15. School Psychologists in Support of Transgender and Gender Diverse Students in Light of California's AB 1266 (School Success and Opportunity Act): Implications and Opportunities
16. US Food and Drug Administration Expanded Adjuvant Indication of Abemaciclib in High-Risk Early Breast Cancer
17. Abstract P2-13-03: Feasibility of generating an external control comparator using RWD by matching with previously conducted RCTs: CDK4/6 Inhibitors for the treatment of Metastatic Breast Cancer
18. An Empirical Investigation of Bayesian Clinical Trial Design in Metastatic Breast Cancer
19. US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer
20. Regulatory implications of ctDNA in immuno-oncology for solid tumors
21. School Psychologists in Support of Transgender and Gender Diverse Students in Light of California’s AB 1266 (School Success and Opportunity Act): Implications and Opportunities
22. FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated Tumors
23. FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer
24. U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review
25. U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review
26. Abstract P2-11-05: Generating real-world external comparators for randomized clinical trials (RCTs) in metastatic breast cancer (mBC) using electronic health records (EHRs)
27. Inferring Species-Level Phylogenies and Taxonomie Distinctiveness Using Multilocus Data in Sistrurus Rattlesnakes
28. Unifying Vertical and Nonvertical Evolution: A Stochastic ARG-based Framework
29. Three roads diverged? Routes to phylogeographic inference
30. Subgroup Analyses in Oncology Trials: Regulatory Considerations and Case Examples
31. Two-way Bayesian hierarchical phylogenetic models: An application to the co-evolution of gp120 and gp41 during and after enfuvirtide treatment
32. Survival benefit of nephrectomy prior to immunotherapy-based combinations in patients with metastatic renal cell carcinoma: An FDA pooled analysis.
33. Overall survival in patients with breast cancer treated with a CDK 4/6 inhibitor plus fulvestrant: A U.S. Food and Drug Administration pooled analysis.
34. An FDA-pooled analysis of frontline combination treatment benefits by risk groups in metastatic renal cell carcinoma (mRCC).
35. Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience
36. Do Student Paper Competitions Really Matter?
37. Overall Survival in Patients with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer Treated with a CDK 4/6 Inhibitor Plus Fulvestrant: A U.S. Food and Drug Administration Pooled Analysis
38. Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case Studies
39. FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer
40. FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase–zzxf Injection for Subcutaneous Use in Patients with HER2-positive Breast Cancer
41. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer
42. FDA Approval Summary: Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2-positive Early Breast Cancer
43. FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1
44. FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer
45. Abstract PD4-08: An FDA analysis of survival outcomes comparing adjuvant paclitaxel and trastuzumab trial (APT) to an external control from historical clinical trials
46. Outcomes of Older Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor–Negative Metastatic Breast Cancer Treated With a CDK4/6 Inhibitor and an Aromatase Inhibitor: An FDA Pooled Analysis
47. An Empirical Investigation of Bayesian Clinical Trial Design in Metastatic Breast Cancer
48. StepBrothers: inferring partially shared ancestries among recombinant viral sequences
49. Smooth Skyride through a Rough Skyline: Bayesian Coalescent-Based Inference of Population Dynamics
50. U.S. Food and Drug Administration Benefit‐Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.